Although it’s not yet approved by the Food and Drug Administration (FDA) the next major advancement for chimeric antigen receptor (CAR T) cell therapy is targeting multiple myeloma, and could very well transform oncology.
Myeloma is the most common blood cancer in adults, and there’s never been a curative therapy, but Moffitt researchers are leaders in advancing the field of CAR T therapy and multiple myeloma clinical trials provide patients with exciting opportunities to be among the first to receive and benefit from promising new treatments before those options are widely available. Participants also help to accelerate the development of next-generation treatments that will benefit all current and future cancer patients.
"Myeloma is a very active area for cellular therapies and is going to become even more active." said Dr. Jason Brayer, Assistant Member, Malignant Hematology Program "We currently have several CAR T cell trials active for multiple myeloma as well as several other cellular therapy trials. And we are bringing on a few more that should be opening in the near future."
Moffitt Cancer Center's Malignant Hematology Oncology Program is actively participating on the following trials:
- CARSgen BCMA CAR T cell in relapsed/refractory myeloma (RRMM) – Phase Ib/II trial
- Bluebird Bio / BMS (Celgene) KarMMa-2 BCMA CAR T cell therapy in RRMM - Phase II trial
- GSK NY-ESO-1 transgenic TCR cellular therapy for RRMM
To refer a patient to Moffitt, complete our online form or contact a physician liaison for assistance or support. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.